Efficacy and Safety of Direct-Acting Antiviral Therapies and Baseline Predictors for Treatment Outcomes in Hepatitis C Patients in China
![](local/cache-gd2/59/ba2cc860a1a10e461dfbd5dca6e863.jpg?1658184133)
The data on direct-acting antivirals (DAAs) in chronic hepatitis C (CHC) patients in southern China with multiple genotypes circulating are limited.
A multicenter, real-world study, published in the Journal of Medical Virology, evaluated the efficacy and safety of DAA regimens among CHC patients in Guangdong, China.
The study abstract can be accessed here.